Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase NA 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Classical hematology 1

Conditions

Hematologic Neoplasms 2Pseudomonas Infections 1Pneumonia 1Gram-Negative Bacterial Infections 1Febrile Neutropenia 1Bacteremia 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 37Zoledronic Acid 34Letrozole 34Sodium Chloride 33Carboplatin 33Bupivacaine 31Bevacizumab 31Docetaxel 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Gemcitabine 22Oxaliplatin 21Morphine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × ceftolozane, tazobactam drug combination × Clear all
NCT04673175 2026-01-21

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

Weill Medical College of Cornell University

Phase 4 Terminated
17 enrolled 20 charts
Other hematologic neoplasm

Pneumonia, Pseudomonas Infections, Bacteremia, Gram-Negative Bacterial Infections, Hematologic Neoplasms

NCT05061654 2023-08-14

CEF-10

Hamad Medical Corporation

Phase 4 Withdrawn
Classical hematologyOther hematologic neoplasm

Hematologic Neoplasms, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡